• About us
• Contact

Advertisement

Person › Details

Helen Tayton-Martin (Adaptimmune Therapeutics plc (Nasdaq: ADAP))

Tayton-Martin, Helen (Adaptimmune 201703– CBO before COO + Co-Founder before Avidex/Medigene)

 

	Organisation	Adaptimmune Therapeutics plc (Nasdaq: ADAP)
	Group	Adaptimmune (Group)
	Product	TCR engineered T-cells
	Product 2	cell therapy

Record changed: 2024-07-17

Advertisement

More documents for Helen Tayton-Martin

• [1] Adaptimmune Therapeutics plc. (1/14/20). "Press Release: Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies". Tokyo, Philadelphia, PA & Oxfordshire....
• [2] Adaptimmune Therapeutics plc. (7/25/19). "Press Release: Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS". Philadeliphia, PA & Oxfordshire....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.